Publications by authors named "H L Parnes"
Article Synopsis
- Prostate cancer (PCA) treatment decisions must balance the benefits of controlling cancer against potential treatment-related side effects.*
- This study compared long-term complications from PCA treatments like prostatectomy and radiotherapy to those in a general older male population using data from two major clinical trials linked to Medicare records.*
- Results showed that PCA treatments significantly increased the risk of urinary and sexual complications, with prostatectomy presenting a 7.23 times higher risk and radiotherapy a 2.76 times higher risk compared to untreated patients. Additionally, radiotherapy patients faced nearly three times the risk of developing bladder cancer.*
We performed a clinical trial in patients with non-muscle-invasive (NMI) urothelial cancer randomized (2:1) to the EGFR tyrosine kinase inhibitor erlotinib or placebo (either orally once weekly × 3 doses prior to scheduled surgery) to assess for a difference in EGFR phosphorylation in tumor-adjacent normal urothelium <24 hours post-study dose and tolerance of weekly erlotinib therapy. Thirty-seven volunteers (6 female/31 male; mean age 70; 35 White/2 non-White) with confirmed or suspected NMI urothelial cancer were enrolled into either erlotinib (n = 24; 900 mg-13, 600 mg-11) or placebo (n = 13). IHC assessment of phosphorylated and total EGFR in tumor-adjacent normal urothelium (20 erlotinib and 9 placebo subjects) or tumor (21 erlotinib and 11 placebo subjects) at study end showed no significant difference between those receiving erlotinib or placebo.
View Article and Find Full Text PDFPurpose: Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare genitourinary (GU) tumors in a dose-escalation phase I study. We report the final data analysis of the safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) of the phase I patients and seven expansion cohorts.
Methods: This is an investigator-initiated, multicenter, phase I trial.
Article Synopsis
- MRI/ultrasound fusion-guided targeted biopsy (TBx) is essential for effective management of prostate cancer by helping with precise risk stratification.
- This study compared the performance of two versions of the PI-RADS scoring system (v2.0 and v2.1) in predicting changes in cancer severity after TBx and subsequent radical prostatectomy (RP).
- Results showed no significant differences in upgrade or downgrade rates between the two versions, indicating that both versions are equivalent in assessing clinically significant prostate cancer.